Gapping down
In reaction to disappointing earnings/guidance:
- HCSG -1.7%, (guidance), JBHT -1.3%
Other news:
- CLDX -45.6% (reports that the randomized Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint)
- WPP -4.8% (announces Sir Martin Sorrell has stepped down as Chief Executive Officer of WPP with immediate effect)
- BPMC -3.5% (reports proof-of-concept data for highly selective RET Inhibitor BLU-667)
- NLNK -3.4% (reports initial data from Phase 1 NLG2105 study )
- CLVS -3.4% (commences separate underwritten public offerings of convertible senior notes and common stock)
- JMEI -2.5% (CFO Yunsheng Zheng resigned effective April 11 for personal reasons)
- HTHT -2.4% (reports blended occupancy rate of 83.7% versus 83.9% last year; reports Q1 blended RevPar of RMB 173 mln versus RMB 152 mln)
- BUD -0.5% (negative article from Barrons)
Analyst comments:
- KHC -1.2% (downgraded to Underperform from Neutral at Credit Suisse)
- CROX -2.7% (downgraded to Negative from Neutral at Susquehanna)
- SJM -1.1% (downgraded to Underperform from Neutral at Credit Suisse)
- DF -1% (downgraded to Sell from Neutral at Goldman)